XML 24 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2018 $ 15,794 $ 56 $ 27,210 $ (5,958) $ (2,459) $ (4,142) $ 14,707 $ 1,087
Beginning balance, shares at Dec. 31, 2018   1,196            
Net income (loss) (1,000)     (999)     (999) (2)
Other comprehensive income (loss) 160       147   147 14
Issuance of Treasury Shares 6   (8)     14 6  
Issuance of Shares, shares   2            
Stock-based compensation expense 119   119       119  
Transactions with non-controlling interests (8)             (8)
Other (8)   (8)       (8)  
Ending balance at Dec. 31, 2019 15,063 $ 56 27,312 (6,956) (2,312) (4,128) 13,972 1,091
Ending balance, shares at Dec. 31, 2019   1,198            
Net income (loss) (4,099)     (3,990)     (3,990) (109)
Other comprehensive income (loss) (30)       (86)   (86) 56
Issuance of Shares, value 1           1  
Issuance of Shares, shares   4            
Stock-based compensation expense 129   129       129  
Transactions with non-controlling interests (2)             (2)
Ending balance at Dec. 31, 2020 11,061 $ 57 27,443 (10,946) (2,399) (4,128) 10,026 1,035
Ending balance, shares at Dec. 31, 2020   1,202            
Net income (loss) 456     417     417 39
Other comprehensive income (loss) (391)       (283)   (283) (107)
Issuance of Shares, shares   7            
Stock-based compensation expense 119   119       119  
Transactions with non-controlling interests (2)             (2)
Ending balance at Dec. 31, 2021 $ 11,244 $ 57 $ 27,561 $ (10,529) $ (2,683) $ (4,128) $ 10,278 $ 966
Ending balance, shares at Dec. 31, 2021   1,209